{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:12:36Z","timestamp":1770754356924,"version":"3.50.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.vaccine.2021.06.005","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T03:25:19Z","timestamp":1625023519000},"page":"4545-4554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months"],"prefix":"10.1016","volume":"39","author":[{"given":"Lars","family":"\u00d8stergaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Vesikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly D.","family":"Senders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9705-4766","authenticated-orcid":false,"given":"Carl-Erik","family":"Flodmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Kosina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Qing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Absalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-0748","authenticated-orcid":false,"given":"Shannon L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Maansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Beeslaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.06.005_b0005","unstructured":"Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62:1-28. https:\/\/dx.doi.org\/rr6202a1 [pii]."},{"key":"10.1016\/j.vaccine.2021.06.005_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2021.06.005_b0015","unstructured":"Centers for Disease Control. Enhanced meningococcal disease surveillance report, 2017, https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2017.pdf; 2017 [accessed May 10, 2019]."},{"key":"10.1016\/j.vaccine.2021.06.005_b0020","unstructured":"European Centre for Disease Prevention and Control. Annual epidemiological report for 2017 invasive meningococcal disease, https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/AER_for_2017-invasive-meningococcal-disease.pdf; 2019 [accessed April 24, 2019]."},{"key":"10.1016\/j.vaccine.2021.06.005_b0025","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3201\/eid2503.181574","article-title":"University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013\u20132018","volume":"25","author":"Soeters","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.06.005_b0030","first-page":"606","article-title":"Serogroup B meningococcal disease outbreak and carriage evaluation at a college - Rhode Island, 2015","volume":"64","author":"Soeters","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2021.06.005_b0035","unstructured":"European Centre for Disease Prevention and Control (ECDC). Surveillance Report. Annual Epidemiological Report for 2016. Invasive Meningococcal Disease, https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/AER_for_2016-invasive-meningococcal-disease_1.pdf; 2018 [accessed May 29, 2019]."},{"key":"10.1016\/j.vaccine.2021.06.005_b0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14760584.2018.1483726","article-title":"From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine","volume":"17","author":"Perez","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.06.005_b0045","unstructured":"Trumenba\u00ae (meningococcal group B vaccine). Full Prescribing Information, Wyeth Pharmaceuticals Inc (a subsidiary of Pfizer Inc), Philadelphia, PA, 2018."},{"key":"10.1016\/j.vaccine.2021.06.005_b0050","unstructured":"European Medicines Agency. EPAR Summary for the Public: Trumenba, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/004051\/WC500228998.pdf; 2017 [accessed July 12, 2019]."},{"key":"10.1016\/j.vaccine.2021.06.005_b0055","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.vaccine.2018.11.073","article-title":"Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents","volume":"37","author":"Vesikari","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.06.005_b0060","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1473-3099(16)30314-0","article-title":"Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Marshall","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.06.005_b0065","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/INF.0000000000001124","volume":"35","author":"Muse","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.06.005_b0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jpids\/piv064","article-title":"Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2021.06.005_b0075","first-page":"673","article-title":"Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents","volume":"35","author":"Vesikari","year":"2015","journal-title":"J Ped Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2021.06.005_b0080","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization\u2013international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.06.005_b0085","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.06.005_b0090","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2018.12.059","article-title":"Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine","volume":"37","author":"Nolan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.06.005_b0095","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.vaccine.2014.07.049","article-title":"A randomized, phase 1\/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants","volume":"32","author":"Martinon-Torres","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.06.005_b0100","doi-asserted-by":"crossref","unstructured":"Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013;381:825-35. https:\/\/dx.doi.org\/S0140-6736(12)61961-8 [pii] 10.1016\/S0140-6736(12)61961-8.","DOI":"10.1016\/S0140-6736(12)61961-8"},{"key":"10.1016\/j.vaccine.2021.06.005_b0105","unstructured":"Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report, 2017, https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html; [accessed February 21, 2019]."},{"key":"10.1016\/j.vaccine.2021.06.005_b0110","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/INF.0000000000000866","article-title":"Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial","volume":"34","author":"Baxter","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.06.005_b0115","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.06.005_b0120","doi-asserted-by":"crossref","first-page":"e20162193","DOI":"10.1542\/peds.2016-2193","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2021.06.005_b0125","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.06.005_b0130","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines\u2013Advisory Committee on Immunization Practices (ACIP), 2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2021.06.005_b0135","unstructured":"Centers for Disease Control and Prevention. Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger: United States 2019, https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/child-adolescent.html; 2019 [accessed March 5, 2019]."},{"key":"10.1016\/j.vaccine.2021.06.005_b0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.vaccine.2016.11.009","article-title":"Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial","volume":"35","author":"Iro","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.06.005_b0145","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.06.005_b0150","doi-asserted-by":"crossref","first-page":"E1276","DOI":"10.1503\/cmaj.161288","article-title":"Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules","volume":"189","author":"Sadarangani","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2021.06.005_b0155","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.vaccine.2015.06.079","article-title":"Meningococcal serogroup B vaccine (4CMenB): booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children","volume":"33","author":"Vesikari","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21007179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21007179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:59:23Z","timestamp":1759402763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21007179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":31,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0264410X21007179"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.005","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}